GNAQ Q209P

CI-VAR-00003517Explore in graph →NP_002063.2:p.Gln209ProNM_002072.4:c.626A>CClinVar 375957 CIViC 604 rs121913492

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma2
GNAQ Q209P	PLX4720	Predictive	D	Supports Resistance	3	accepted	EID1537 Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequenci… (full text at CIViC) PMID 24504448 · Turajlic et al., 2014 · Open in CIViC	civic
GNAQ Q209P	Vemurafenib	Predictive	C	Supports Resistance	2	accepted	EID1533 A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was ide… (full text at CIViC) PMID 24504448 · Turajlic et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.